The Consumer Medicine Information (CMI) for MenQuadfi, Influvac Tetra and Gardasil 9 is available at www.medsafe.govt.nz Trademarks are property of their respective owners.
A prescription may not be required for some vaccines in pharmacy. Ask your pharmacist.
AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus RSV-A and RSV-B subtypes in adults 60 years of age and older. AREXVY is a prescription medicine; it is not funded and charges will apply. A single dose (0.5 mL) contains 120 micrograms of RSVPreF3 antigen adjuvanted with AS01E, composed of the plant extract Quillaja saponaria Molina, fraction 21 (QS-21) (25 micrograms) and 3-O-desacyl-4’-monophosphoryl lipid A (MPL) from Salmonella minnesota (25 micrograms). AREXVY should not be administered if you are hypersensitive to any component of this vaccine. AREXVY has risks and benefits – ask your doctor if AREXVY is right for you. Use strictly as directed. Side effects include: joint pain, injection site reactions including pain, swelling and redness, headache, runny nose, fatigue, fever and chills. This is not a full list. Vaccination with AREXVY may not fully protect all vaccine recipients. If you have side effects, see your doctor, pharmacist or healthcare professional. Normal doctor’s charges apply. Additional product information and Consumer Medicine Information (CMI) is available at www.medsafe.govt.nz
BEXSERO (Multicomponent meningococcal group B vaccine) is for immunisation against invasive disease caused by N. meningitidis group B from 2 months of age or per official recommendations. BEXSERO is a prescription medicine and is funded as part of the National Immunisation Schedule. See Pharmaceutical Schedule for full funding criteria. BEXSERO is also available for private purchase – normal doctor’s fees apply. One 0.5 ml dose BEXSERO contains 50 mcg of each N. meningitidis group B component (Neisseria Heparin Binding Antigen fusion protein, Neisseria Adhesin A protein and Factor H Binding Protein fusion protein), as well as 25 mcg outer membrane vesicles from N. meningitidis group B strain NZ98/254. BEXSERO has risks and benefits. Ask your doctor if BEXSERO is right for you. Use strictly as directed. Very common side effects for infants, toddlers, and children (up to 10 years of age) include tenderness at the injection site, fever, and irritability. In adolescents (from 11 years of age) and adults, very common side effects are pain at the injection site, nausea, and headache. If you or your child have side effects, see your doctor. For more information, including full product details, see BEXSERO Consumer Medicine Information (CMI) at www.medsafe.govt.nz
BOOSTRIX (combined diphtheria, tetanus, and acellular pertussis (dTpa or Tdap) vaccine), a prescription medicine, is indicated for booster immunisation of people aged 4 years and older against diphtheria, tetanus, and pertussis (whooping cough). A 0.5 mL dose contains not less than 2.5 LfU of diphtheria toxoid, not less than 5 LfU of tetanus toxoid, and three purified antigens of Bordetella pertussis (8mcg of pertussis toxoid, 8 mcg of filamentous haemagglutinin, and 2.5 mcg of pertactin). BOOSTRIX is funded for 11 year olds, pregnant women in the second or third trimester of each pregnancy, and for primary caregivers of infants admitted to Intensive Care Units for more than 3 days if maternal vaccination was not given more than 2 weeks before birth. It is also funded for people from 65 years old, and people from 45 years old who have not had 4 previous doses of tetanus vaccine, for vaccination of previously unimmunised or partially immunised patients, for revaccination following immunosuppression and for boosting of patients with tetanus-prone wounds. See full funding criteria at pharmac.govt.nz. Normal doctor’s charges apply. BOOSTRIX has risks and benefits. Ask your doctor or pharmacist if BOOSTRIX is right for you. Use strictly as directed. If you have side effects, see your doctor, pharmacist or healthcare professional. Additional Consumer Medicine Information (CMI) is available at www.medsafe.govt.nz
PRIORIX (Live trivalent attenuated measles, mumps and rubella vaccine)
is a
prescription medicine. Each 0.5 mL dose of the reconstituted vaccine
contains not less than 103.0 CCID50 of the Schwarz measles, not less than
103.7 CCID50 of the RIT 4385 mumps (derived from
Jeryl Lynn strain), and not less than 103.0 CCID50 of the Wistar RA 27/3 rubella virus
strains.
PRIORIX is indicated for active immunisation against measles, mumps
and rubella. The
use of PRIORIX should be in accordance with official recommendations. Use
strictly as directed.
PRIORIX is funded as part of the National Immunisation
Schedule. See
Pharmaceutical Schedule for full funding criteria.
SHINGRIX (Recombinant Varicella Zoster Virus Glycoprotein E antigen 50 mcg (AS01B adjuvanted vaccine)) is indicated for the prevention of herpes zoster and post-herpetic neuralgia in adults 50 years of age or older and for adults 18 years of age or older who are at increased risk of herpes zoster. SHINGRIX, a prescription medicine, is funded for people aged 65 years. From 1 July 2024, SHINGRIX is also funded for certain individuals 18 years and over at higher risk of shingles. See full funding criteria at pharmac.govt.nz. Costs will apply if SHINGRIX is not funded. A single 0.5 mL dose contains 50 mcg of gE antigen, adjuvanted with AS01B (composed of the plant extract Quillaja saponaria saponin (QS-21) (50 mcg) and 3-O-desacyl-4’-monophosphoryl lipid A (MPL) from Salmonella minnesota (50 mcg) plus excipients). SHINGRIX should not be administered if you are hypersensitive to any component of this vaccine. SHINGRIX has risks and benefits – ask your doctor if SHINGRIX is right for you. Use strictly as directed. Normal doctor’s charges apply. Side effects: Adults ≥50 years: pain, redness and swelling at the injection site, muscle pain, fatigue, headache, shivering, fever, and gastrointestinal symptoms. Adults at increased risk of shingles between the ages of 18 to 49 years are more likely to experience side effects such as pain at the injection site, fatigue, muscle pain, headache, shivering and fever compared to those aged ≥50 years. This is not a full list. Vaccination with SHINGRIX may not protect all vaccine recipients. If you have side effects, see your doctor, pharmacist or healthcare professional. Additional product information and Consumer Medicine Information (CMI) is available at www.medsafe.govt.nz
Trademarks are property of their respective owners. ©2025 GSK group of companies or its licensor. GlaxoSmithKline NZ Limited, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500. TAPS NP22443-PM-NZ-AVU-WCNT-240002 Date of Approval: 03 2025 Date of Expiry: 03 2027
